semaglutide death The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications The FDA has issued a

Clinicians should prioritize early recognition and targeted monitoring of high-risk neurological manifestations

While they arent brand-name, they provide a bridge for patients who are priced out of the traditional system or who are facing local shortages of Zepbound or Wegovy

No acids, no enzymes, no chemical solvents

Constipation becomes the dominant side effect for many patients after nausea subsides

The recommended schedule of dosing is at night to mimic the effects of natural growth hormone release

Understanding that GLP-1s affect not only appetite and weight but also brain chemistry puts you in a stronger position to recognize early warning signs